The Food and Drug Administration’s (FDA) decision to authorize the Novavax COVID-19 vaccine for emergency use may be delayed due to the FDA reviewing changes to the company’s manufacturing process.
Novavax told The Epoch Times that the company updated the FDA on changes to its manufacturing process on June 3, days before the advisory committee was scheduled to review its vaccine’s safety and efficacy data.
The committee on June 7 voted 21–0 with one abstention, after seven hours of discussion, agreeing that the benefits of a 2-dose Novavax vaccine outweighed its risk for use in adults aged 18 and older.
“FDA will carefully review this and any additional information submitted by the firm as part of its ongoing assessment and prior to authorizing the vaccine for emergency use,” the FDA spokesperson Abby Capobianco told CNBC….